How effective is Alpelisib in the treatment of breast cancer?

Alpelisib (Alpelisib)-Piqray is an oral PI3K inhibitor that has been approved for the treatment of patients with HR-positive, HER2-negative advanced breast cancer who have PIK3CA gene mutations. The drug's efficacy has been verified in multiple clinical trials, especially when used in combination with fulvestrant (fulvestrant). Apelvis has shown significant therapeutic effects for breast cancer patients who are resistant to traditional endocrine therapy.

In a pivotal Phase III clinical trialthe efficacy of apelixid in combination with fulvestrant in patients with advanced breast cancer has received widespread attention. This study shows that patients treated with apelvis combined with fulvestrant have significantly longer progression-free survival (PFS) and a significantly higher treatment response rate. This result provides an effective alternative treatment, especially for patients who are resistant to endocrine therapy. Patients' quality of life improves, treatment is well tolerated, and side effects are generally controllable. Common side effects include hyperglycemia, rash, and diarrhea.

In addition, Apelvis has also shown a relatively durable effect in some PIK3CA mutated breast cancer patients. Especially for those patients who have already received chemotherapy or other targeted therapies, apelvis can still play a role in slowing the progression of the disease and improving the patient's prognosis.

To sum up, apelvis, as a targeted drug for the treatment of breast cancer, has proven its significant therapeutic effect in multiple clinical trials. Especially when used in combination with fulvestrant, it can effectively prolong the progression-free survival of patients with advanced breast cancer, providing a new treatment option for drug-resistant patients. By precisely targeting the PI3K pathway, Apelvis brings better treatment prospects to breast cancer patients.

Reference materials:https://go.drugbank.com/drugs/DB12015